Also in this week's issue of C&EN (by Michael McCoy):
Despite winning US Food and Drug Administration approval for a new antibiotic last year, Achaogen has filed for bankruptcy. The South San Francisco–based biotech firm launched the antibiotic, Zemdri (plazomicin), in July for adults with complicated urinary tract infections. However, by the end of the year the drug had brought in only $800,000 in sales. Achaogen hopes to sell off its assets, including Zemdri, by June 13.There's a little factlet for those of us who bemoan the state of the antibiotics pipeline.
No comments:
Post a Comment
looks like Blogger doesn't work with anonymous comments from Chrome browsers at the moment - works in Microsoft Edge, or from Chrome with a Blogger account - sorry! CJ 3/21/20